Loading company…
Noa Therapeutics develops treatments for inflammatory and immune diseases affecting the skin and gut barrier.
Founded in 2022 and based in Toronto, Noa Therapeutics develops treatments for inflammatory and immune diseases, particularly those affecting the skin and gut barrier. Its drug candidate NOA-104 is designed to target three disease drivers. In March 2024, the company raised pre-seed funding led by UCeed Haskayne Student Fund, with Archangel, NorthSpring Capital Partners, Ontario Centre of Innovation, and Phoenix Fire participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in